

- 4 -

REMARKS


As per Applicant's Agent's discussion with Examiner Vickie Kim on October 17, 2002, U.S. Patent No. 5,342,625 has been reviewed in detail and the present amendments have been made consistent with the Examiner's recommendations at that time. Claims 24 and 25 have been added consistent with Examples 1 to 8 on page 13 of the disclosure. Full reconsideration is therefore requested. It is presumed therefore that all claims now stand allowable.

Attached hereto as **Exhibit A** is a marked-up version of the changes made to the claims by the present amendment. Exhibit A is entitled "EXHIBIT A - CLAIMS WITH MARKINGS TO SHOW CHANGES".

Attached hereto as **Exhibit B** is a clean set of all pending claims following entry of this amendment. Exhibit B is entitled: "EXHIBIT B - CLEAN SET OF ALL PENDING CLAIMS FOLLOWING ENTRY OF THE PRESENT AMENDMENT". All of the currently pending claims are consolidated in this list for the convenience of the Examiner.

If the Examiner has any questions, she is respectfully requested to contact Applicants' Agent, Neil H. Hughes at (905) 771-6414 at her convenience.

Respectfully submitted,



Neil H. Hughes, P.Eng.
Registration No. 33,636
Agent for Applicant

NHH:mse
Enclosures

- 5 -

Amendment A
U.S. Application Serial No. 09/783,969
Group Art Unit 1614

EXHIBIT A

CLAIMS WITH MARKINGS TO SHOW CHANGES

Please amend the claims as follows.

1. (Twice Amended) A pharmaceutical composition [comprising an emulsion] consisting essentially of a microemulsion preconcentrate including a cyclosporin dissolved in a solvent system comprising substantially fully acetylated monoglycerides having a minimum acetylation of 96%, a hydrophilic organic solvent and at least two surfactants.

15. (Twice Amended) A pharmaceutical composition comprising a micro emulsion preconcentrate yielding a droplet size in an emulsion of substantially less than 2000 A as measured by the light transmittance through a cell, and including a cyclosporin dissolved in an acetylated monoglyceride lipophilic solvent, and [a] 3 surfactants.

Please cancel claim 16.

[16. The composition of claim 1 in the form of a microemulsion preconcentrate.]

- 6 -

23. (Amended) The composition of claim 15 wherein said surfactants [further comprises two surfactants, one of which is a] include a polyoxyethylene glycolated natural or hydrogenated vegetable oil and [the second of which is] a polyoxyethylene-sorbitan-fatty acid ester.

Please add the following claims.

24. A pharmaceutical composition comprising cyclosporine, Myvacet 9-45, propylene glycol, Cremophor RH40, and Polysorbate 20.

25. A pharmaceutical composition comprising cyclosporine, Myvacet 9-45, propylene carbonate, Cremophor RH40, and Polysorbate 20.